Neeta Pandit-Taskar, MD
Nuclear Medicine Physician
Molecular Imaging with PET/CT and PET/MR; Theranostics; Radiolabeled Antibodies, Small Molecules and Peptides, Beta and Alpha Emitters for Imaging and Targeted Cancer Therapies; Pediatric Malignancies
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Pandit-Taskar accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, Lady Hardinge Medical College (India)
Mount Sinai Medical Center (New York)
Memorial Sloan Kettering Cancer Center
I am a clinician-scientist who is board certified in nuclear medicine and nuclear cardiology. I have more than two decades of broad experience in clinical nuclear medicine and related research. I joined MSK in 2000. I am also Clinical Director of the Center for Radioimmunotargeted Imaging and Theranostics of the Ludwig Center for Cancer immunotherapy. Before coming to MSK, I was head of the nuclear medicine department at a cancer center in India. At MSK, I collaborate closely with medical oncologists and surgeons to provide conventional and novel methods of diagnosing and treating patients with radiolabled agents in a variety of malignancies. I have a special interest in treating pediatric cancers.
I provide clinical care in all aspects of radiopharmaceutical imaging (PET/CT, PET/MR, SPECT/CT, nuclear cardiology) and radionuclide therapy, and also conduct research involving the development of novel methods for diagnosis and treating cancers using radiolabeled agents. Over the years my work, both clinical and research, has increasingly focused on therapeutic applications, including theranostics – which is the combination of therapies and diagnostics – and treatment response assessment, with large and small radiolabeled molecular targeting agents.
My research involves radioimmunotargted agents, small molecules and peptides, alpha emitters, and the use of novel PET tracers and techniques like PET/CT and PET/MR for early assessment of disease status and response. As the principal investigator of a National Institutes of Health (NIH) RO1 grant from the National Cancer Institute, I am investigating new imaging techniques to detect and monitor neuroblastoma in children with PET/MR. The goal is to reduce radiation exposure and provide a rapid single-day imaging assessment to monitor disease and therapy response. I am also co-leading studies in theranostics in pediatric malignancies such as neuroblastoma, brain tumors, and other tumors including desmoplastic small round cell tumors.
My focus is on developing novel theranostic strategies with radiopharmaceuticals. I am studying the use of radiolabeled monoclonal antibodies to detect and treat cancers. My early research focused on the optimization of biodistribution and understanding the kinetics of radioimmunotargeted agents in variety of cancers. These include: Radiolabeled antibodies 8H9 and 3F8 for pediatric cancers such as metastatic neuroblastoma and brain tumors, and radioimmunoPET imaging and radioimmunotherapy for renal cancer, prostate cancer, ovarian cancer, pancreatic cancer, lymphoma, and colon cancer.
More recently, I have extended this work to utilize and optimize smaller molecules, ligands, and peptides for diagnoses and treatment. I have also looked at the use of alpha-emitter-conjugated radiolabeled antibodies in the treatment of malignancies. I am studying methods to improve the delivery of radiation to the tumors using image assessment and dose estimations to provide personalized therapy. Using novel hybrid PET/MR imaging, I am studying novel tracers to better diagnose and monitor treatment effect, which can also help guide management and therapy planning in the future. This will allow for lower radiation exposures when imaging pediatric patients.
I routinely perform radiopharmaceutical therapy with 131I-MIBG for neuroendocrine tumors including neuroblastoma, pheochromocytoma, and paraganglioma; bexxar and zevalin therapy for lymphoma; and Radium-di-chloride (xofigo) or samarium radionuclides to treat metastatic bone disease pain. I also perform microsphere therapy for liver metastasis (SIRT) with 90 Y sirspheres/theraspheres.
Awards and Honors
- Castle Connolly: New York Magazine Top Doctors (2012-2020)
- Clinical Trials Investigated by Dr. Pandit-Taskar
- A Phase I/II Study of [225Ac]-FPI-1434 in People with Advanced or Metastatic Solid Tumors
- A Phase I/II Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in People with Advanced Solid Tumors
- A Phase I/IIA Study of 64Cu-SARTATE and 67Cu-SARTATE for Imaging and Treating Children and Young Adults with High-Risk Neuroblastoma
- Clinical Trials Co-Investigated by Dr. Pandit-Taskar
- A Phase I Study of BAY 2701439 in People with HER2-Expressing Cancers
- A Phase I Study of CLR 131 in Children, Adolescents, and Young Adults with Recurrent or Persistent Solid Tumors, Lymphoma, and Brain Tumors
- A Phase I Study of JNJ-69086420 for Advanced Prostate Cancer
- A Phase I Study of MEDI9253 and Durvalumab in People with Advanced or Metastatic Solid Tumors
- A Phase I Study of PF-07062119 Immunotherapy in People with Advanced Digestive Cancers
- A Phase II Study Assessing the Use of Omburtamab Radioimmunotherapy for Recurrent Medulloblastoma and Ependymoma in Children and Adolescents
- A Phase II Study of 131I-Omburtamab plus Radiotherapy in People with Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum
- A Phase II Study of CLR 131 in People with Central Nervous System Lymphoma
- A Phase II Study of Nivolumab Immunotherapy in Combination with 177Lu-Girentuximab for Advanced Kidney Cancer
- A Pilot Phase II Study of Targeted Radiotherapy with 131I-MIBG and Arsenic Trioxide in Patients with Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors
- A Pilot Study of 131-I Apamistamab and CAR T-Cell Therapy in People with Recurrent or Persistent Leukemia or Lymphoma
- CD8+ T Cell Imaging During Immunotherapy Before Surgery in People with Melanoma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Visit PubMed for a full listing of Dr. Pandit-Taskar’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Neeta Pandit-Taskar discloses the following relationships and financial interests:
Provision of Services
Y-mAbs Therapeutics, Inc.
Provision of Services (uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.